Current pharmacotherapy for methicillin-resistant
Linezolid
ceftaroline
ceftobiprole
clindamycin
delafloxacin
lefamulin
minocycline
omadacycline
rifampin
vancomycin
Journal
Expert opinion on pharmacotherapy
ISSN: 1744-7666
Titre abrégé: Expert Opin Pharmacother
Pays: England
ID NLM: 100897346
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
pubmed:
10
12
2021
medline:
2
2
2022
entrez:
9
12
2021
Statut:
ppublish
Résumé
Currently, several antibiotics are active against methicillin-resistant In this narrative review, the authors discuss the characteristics of currently available agents for the treatment of MRSA pneumonia. The availability of different agents with anti-MRSA activity, and approved for the treatment of pneumonia can allow a personalized approach for any given patient based on the severity of the disease, the setting of occurrence, the patient's baseline risk of toxicity and drug interactions, and the possibility of oral therapy whenever early discharge or outpatient treatment are possible. Although some gray areas still remain, like the lack of high certainty evidence on the efficacy of some old agents and on the precise role of companion agents with toxin inhibitory activity in the case of necrotizing pneumonia, the frequent availability of different treatment choices, each with peculiar characteristics, is already allowing an important step toward a precision medicine approach for the treatment of MRSA pneumonia.
Identifiants
pubmed: 34882041
doi: 10.1080/14656566.2021.2010706
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM